FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination

Completed

• Conditions: Oncology; Vaccine Reaction

• Registration Number: NCT05270967
• Lead Sponsor: Kocaeli University

Brief Summary

It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-29
• Primary Completion: 2022-01-10
• Study Completion: 2022-01-10
• Status Verified: 2022-03
• Study First Submitted: 2022-03-05
• Study First Submitted QC: 2022-03-07
• Last Update Submitted: 2022-03-07
• Study First Posted: 2022-03-08
• Last Update Posted: 2022-03-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 129

Inclusion Criteria

• patients referred for post-vaccination FDG PET/CT imaging

Exclusion Criteria

• Disseminated metastatic disease, ipsilateral breast cancer or lymphoma that was likely to involve axilla, and patients who had ipsilateral intense axillary uptake or thyroiditis on their prior imaging, were exclusion criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
to assess the frequency of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine	5 month	Frequency of metabolic changes
to assess the FDG intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine	5 month	FDG intensity of metabolic changes

Trial Locations

Locations (1)

Kocaeli University School of Medicine Dep. of Nuclear Medicine; 🇹🇷 Kocaeli, Turkey